Current Trials
ACTIVELY ENROLLING STUDIES
Acute Coronary Syndrome
TRANSLATE ACS: An observational study to evaluate “real world” effectiveness and use of Prasugrel and other ADP receptor inhibitors among MI patients treated with PCI during index hospitalization.
VISTA-16: A double-blind randomized study to evaluate the safety and efficacy of A-002 when added to atorvastatin plus standard-of-care in subjects with ACS. Subjects will be randomized to either a-002 500mg QD or placebo, in addition to atorvastatin plus standard-of-care, within ≤96 hours of index event diagnosis.
Acute Myocardial Infarction Patients with Low Ejection Fraction <35% (Weak Heart Muscle)
VEST: To find out whether wearing a LifeVest external defibrillator (device that can shock the heart back to a normal rhythm) can prevent death from an abnormal heart rhythm in the two months after a heart attack.
Atrial Fibrillation
ACT V: To evaluate the safety and efficacy of Vernakalant Hydrochloride Injection in patients with recent onset symptomatic atrial fibrillation.
(Temporarily “ON HOLD”)
Carotid Stent
CHOICE: Registry to provide additional information that the commercially available Abbott Vascular Carotid Stent Systems and Embolic Protection Systems can be used successfully by a wide range of physicians under commercial-use conditions.
Congestive Heart Failure
PARADIGM: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction.
Coronary Artery Disease
GE Cath (GE-145-002): To evaluate the effects of GE-145 and a comparator, Iopamidol, on cardio-renal safety in high risk elderly subjects undergoing a coronary catheterization procedure with or without PCI.
Ventral Hernia
VIBE (Post-Market Study): To determine how often hernia recurrence occurs after ventral hernia repair with the Veritas collagen matrix. Study also collects quality of life information.
CENTER FOR CANCER CARE & RESEARCH
|
BREAST |
|
|
NSABP B-43 |
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
|
|
NSABP B-47 |
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node Negative HER2-Low Invasive Breast Cancer |
|
NCIC MA.32 |
A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer |
|
NSMR |
ASBrS Nipple Sparing Mastectomy Registry
|
|
ESOPHAGEAL |
|
|
RTOG 0436 |
A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery
|
|
GYNECOLOGIC |
|
|
GOG 0252 |
A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma |
|
GOG 0262 |
A Randomized Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #7921) in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer
|
|
MULTIPLE MYELOMA |
|
|
Connect MM |
The Multiple Myeloma Disease Registry
|
|
LYMPHOMA |
|
|
LYM 37 |
Rituximab ± Bevacizumab in the Treatment of Patients with Follicular Non-Hodgkin’s Lymphoma: A Randomized, Phase II Trial
|
|
LEUKEMIA |
|
|
Connect CLL |
The Connect CLL Chronic Lymphocytic Leukemia Registry
|
|
LUNG |
|
|
LUN 196 (TOPPS) |
TOPPS: Trial Of Poor Performance Status patients. Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/ Carboplatin/Bevacizumab in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer and ECOG Performance Status 2 |
|
ECLIPSE (LUN 201) |
Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects with Previously Untreated Stage IV Squamous Non Small-Cell Lung Cancer (NSCLC)
|
|
PROSTATE |
|
|
MCC 15008
(Green Tea) |
Phase II, Randomized, Double-blind, Multi-centered Study of Polyphenon E in Men with High-grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical small acinar proliferation (ASAP) |
|
RTOG 0815 |
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
|
|
VTE RISK |
|
CANTARISK VTE
|
Registry on VTE Risk in Outpatients Starting New Chemotherapy for Cancer
|
|
RENAL |
|
|
S0931
|
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study
|
|
MICELLANEOUS |
|
| TCC – Total Cancer Care (MCC14690) |
Total Cancer Care: A Partnership with High Risk and/or Diagnosed Cancer Patients for Life |
FIQCC-P03
|
Total Cancer Care: Florida Initiative for Quality Cancer Care Protocol (Colorectal) |
|
FIQCC-P03
|
Total Cancer Care: Florida Initiative for Quality Cancer Care Protocol (Breast)
|
For More Information:
If you would like additional information about the Center for Research, please send your name, company or practice name, address and telephone number to the following address:
The Watson Clinic Center for Research
1600 Lakeland Hills Blvd
Lakeland, FL 33805
Attn: Noreen McGowan, BSN CCRC Administrative Coordinator
Phone 863-688-6826 · FAX 863-688-5842
Please indicate which of the following type(s) of information you would like:
- Additional information about current protocols
- Center for Research grants
- Contributing to Center for Research funding
- Involvement in Center for Research protocols